Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines (Record no. 44355)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03411nam a22004937a 4500 |
| 001 - CONTROL NUMBER | |
| control field | sulb-eb0022263 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | BD-SySUS |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20160413122239.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 130417s2013 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781461453802 |
| -- | 978-1-4614-5380-2 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/978-1-4614-5380-2 |
| Source of number or code | doi |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | QR180-189.5 |
| 072 #7 - SUBJECT CATEGORY CODE | |
| Subject category code | MJCM |
| Source | bicssc |
| Subject category code | MED044000 |
| Source | bisacsh |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.079 |
| Edition number | 23 |
| 245 10 - TITLE STATEMENT | |
| Title | Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines |
| Medium | [electronic resource] / |
| Statement of responsibility, etc. | edited by Manmohan Singh. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Boston, MA : |
| Name of producer, publisher, distributor, manufacturer | Springer US : |
| -- | Imprint: Springer, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2013. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | X, 370 p. |
| Other physical details | online resource. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS | |
| File type | text file |
| Encoding format | |
| Source | rda |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Critical parameters that govern the optimization of vaccine formulations -- Development of Biophysical assays to better understand vaccine formulation stability -- Rational design of vaccine formulations -- Monitoring stability and efficacy of multi-valent vaccine formulations.- Overcoming challenges of multi component alum formulations.- Delivery of various TLR adjuvants using alum platform -- History of use of emulsions for vaccine delivery -- MF59 o/w emulsion : History and safety over the last 2 decades -- Optimizing novel nanoemulsions for delivery of next generation antigens and adjuvants -- Modulating vaccine responses with innate immunity : Use of PLGA nanoparticles for delivering multiple TLR agonists -- Shape matters : Role of nanoparticle shape in induction of immune responses to a vaccine. . |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Development of new-generation vaccines is now more challenging than ever, as identifying, purifying and evaluating vaccine antigens is a complex undertaking. Most importantly, once the relevant antigens have been identified, key focus then shifts to the development of suitable delivery systems and formulations to achieve maximum in vivo potency with minimum potential side effects. These novel formulations—many of which will be nanoparticulates—can deliver the antigens to the desired site, to the relevant antigen presenting cells, and prevent systemic exposure of the immune potentiators. The proposed book will outline all the critical steps that need to be considered for successful development of various types of nanoparticulate delivery systems for vaccine antigens. These contributions from leading experts in the area of vaccine formulation and delivery systems will tie in what is the most current status, including clinical evaluations with these novel vaccine technologies. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Medicine. |
| Topical term or geographic name as entry element | Immunology. |
| Topical term or geographic name as entry element | Medical microbiology. |
| Topical term or geographic name as entry element | Vaccines. |
| Topical term or geographic name as entry element | Pharmaceutical technology. |
| Topical term or geographic name as entry element | Biomedicine. |
| Topical term or geographic name as entry element | Immunology. |
| Topical term or geographic name as entry element | Medical Microbiology. |
| Topical term or geographic name as entry element | Vaccine. |
| Topical term or geographic name as entry element | Pharmaceutical Sciences/Technology. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Singh, Manmohan. |
| Relator term | editor. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY | |
| Title | Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Printed edition: |
| International Standard Book Number | 9781461453796 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://dx.doi.org/10.1007/978-1-4614-5380-2">http://dx.doi.org/10.1007/978-1-4614-5380-2</a> |
| 912 ## - | |
| -- | ZDB-2-SBL |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | |
| Koha item type | |
No items available.